MEDIFAST INC (MED) Fundamental Analysis & Valuation

NYSE:MED • US58470H1014

9.53 USD
-0.59 (-5.83%)
At close: Mar 12, 2026
9.53 USD
0 (0%)
After Hours: 3/12/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This MED fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

Overall MED gets a fundamental rating of 4 out of 10. We evaluated MED against 37 industry peers in the Personal Care Products industry. While MED has a great health rating, there are worries on its profitability. MED is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. MED Profitability Analysis

1.1 Basic Checks

  • In the past year MED has reported negative net income.
  • In the past year MED had a positive cash flow from operations.
  • Of the past 5 years MED 4 years were profitable.
  • Each year in the past 5 years MED had a positive operating cash flow.
MED Yearly Net Income VS EBIT VS OCF VS FCFMED Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -7.53%, MED is doing worse than 70.27% of the companies in the same industry.
  • The Return On Equity of MED (-9.39%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -7.53%
ROE -9.39%
ROIC N/A
ROA(3y)8.43%
ROA(5y)22.37%
ROE(3y)13.65%
ROE(5y)42.92%
ROIC(3y)N/A
ROIC(5y)N/A
MED Yearly ROA, ROE, ROICMED Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

1.3 Margins

  • With a decent Gross Margin value of 71.33%, MED is doing good in the industry, outperforming 70.27% of the companies in the same industry.
  • In the last couple of years the Gross Margin of MED has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for MED so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 71.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0%
GM growth 5Y-0.9%
MED Yearly Profit, Operating, Gross MarginsMED Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. MED Health Analysis

2.1 Basic Checks

  • MED does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MED has more shares outstanding than it did 1 year ago.
  • MED has less shares outstanding than it did 5 years ago.
  • There is no outstanding debt for MED. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MED Yearly Shares OutstandingMED Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
MED Yearly Total Debt VS Total AssetsMED Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • MED has an Altman-Z score of 4.38. This indicates that MED is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 4.38, MED belongs to the top of the industry, outperforming 83.78% of the companies in the same industry.
  • MED has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.38
ROIC/WACCN/A
WACC8.85%
MED Yearly LT Debt VS Equity VS FCFMED Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

2.3 Liquidity

  • MED has a Current Ratio of 4.69. This indicates that MED is financially healthy and has no problem in meeting its short term obligations.
  • MED's Current ratio of 4.69 is amongst the best of the industry. MED outperforms 83.78% of its industry peers.
  • MED has a Quick Ratio of 4.22. This indicates that MED is financially healthy and has no problem in meeting its short term obligations.
  • MED's Quick ratio of 4.22 is amongst the best of the industry. MED outperforms 91.89% of its industry peers.
Industry RankSector Rank
Current Ratio 4.69
Quick Ratio 4.22
MED Yearly Current Assets VS Current LiabilitesMED Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. MED Growth Analysis

3.1 Past

  • MED shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -186.21%.
  • The Revenue for MED has decreased by -35.96% in the past year. This is quite bad
  • The Revenue for MED have been decreasing by -16.22% on average. This is quite bad
EPS 1Y (TTM)-186.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1750%
Revenue 1Y (TTM)-35.96%
Revenue growth 3Y-37.74%
Revenue growth 5Y-16.22%
Sales Q2Q%-36.9%

3.2 Future

  • Based on estimates for the next years, MED will show a very negative growth in Earnings Per Share. The EPS will decrease by -26.21% on average per year.
  • MED is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -19.23% yearly.
EPS Next Y-14.27%
EPS Next 2Y-26.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-27.82%
Revenue Next 2Y-19.23%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
MED Yearly Revenue VS EstimatesMED Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B
MED Yearly EPS VS EstimatesMED Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

1

4. MED Valuation Analysis

4.1 Price/Earnings Ratio

  • MED reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MED. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MED Price Earnings VS Forward Price EarningsMED Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of MED is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 83.85
EV/EBITDA N/A
MED Per share dataMED EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • MED's earnings are expected to decrease with -26.21% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.21%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. MED Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 9.97%, MED is a good candidate for dividend investing.
  • The stock price of MED dropped by -22.90% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
  • Compared to an average industry Dividend Yield of 1.66, MED pays a better dividend. On top of this MED pays more dividend than 97.30% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, MED pays a better dividend.
Industry RankSector Rank
Dividend Yield 9.97%

5.2 History

  • The dividend of MED decreases each year by -66.94%.
  • MED has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)-66.94%
Div Incr Years0
Div Non Decr Years0
MED Yearly Dividends per shareMED Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2 4 6

5.3 Sustainability

  • MED has negative earnings and hence a negative payout ratio. The dividend may be in danger.
  • MED's earnings and Dividend Rate are declining. This means the current dividend is most likely not sustainable.
DP-1.04%
EPS Next 2Y-26.21%
EPS Next 3YN/A
MED Yearly Income VS Free CF VS DividendMED Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

More info and screens

Find the best dividend stocksShow peers with best dividend

MED Fundamentals: All Metrics, Ratios and Statistics

MEDIFAST INC

NYSE:MED (3/12/2026, 8:04:00 PM)

After market: 9.53 0 (0%)

9.53

-0.59 (-5.83%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)02-17
Earnings (Next)04-27
Inst Owners74.16%
Inst Owner Change-9.18%
Ins Owners3.18%
Ins Owner Change0%
Market Cap104.73M
Revenue(TTM)385.79M
Net Income(TTM)-18.67M
Analysts46.67
Price Target12.24 (28.44%)
Short Float %19.58%
Short Ratio8
Dividend
Industry RankSector Rank
Dividend Yield 9.97%
Yearly Dividend0.02
Dividend Growth(5Y)-66.94%
DP-1.04%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-26.27%
Min EPS beat(2)-99.23%
Max EPS beat(2)46.69%
EPS beat(4)3
Avg EPS beat(4)51.53%
Min EPS beat(4)-99.23%
Max EPS beat(4)199.01%
EPS beat(8)6
Avg EPS beat(8)88.81%
EPS beat(12)9
Avg EPS beat(12)75.52%
EPS beat(16)12
Avg EPS beat(16)64.12%
Revenue beat(2)2
Avg Revenue beat(2)3%
Min Revenue beat(2)0.75%
Max Revenue beat(2)5.26%
Revenue beat(4)4
Avg Revenue beat(4)4.71%
Min Revenue beat(4)0.75%
Max Revenue beat(4)8.75%
Revenue beat(8)7
Avg Revenue beat(8)2.97%
Revenue beat(12)11
Avg Revenue beat(12)3.64%
Revenue beat(16)15
Avg Revenue beat(16)3.64%
PT rev (1m)-20%
PT rev (3m)-20%
EPS NQ rev (1m)-44.44%
EPS NQ rev (3m)-44.44%
EPS NY rev (1m)-1423.08%
EPS NY rev (3m)-1423.08%
Revenue NQ rev (1m)-24.21%
Revenue NQ rev (3m)-24.21%
Revenue NY rev (1m)-22.27%
Revenue NY rev (3m)-22.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.27
P/FCF 83.85
P/OCF 15.26
P/B 0.53
P/tB 0.53
EV/EBITDA N/A
EPS(TTM)-1.75
EYN/A
EPS(NY)-2
Fwd EYN/A
FCF(TTM)0.11
FCFY1.19%
OCF(TTM)0.62
OCFY6.55%
SpS35.1
BVpS18.1
TBVpS18.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.53%
ROE -9.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 71.33%
FCFM 0.32%
ROA(3y)8.43%
ROA(5y)22.37%
ROE(3y)13.65%
ROE(5y)42.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0%
GM growth 5Y-0.9%
F-Score4
Asset Turnover1.56
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 39.42%
Cap/Sales 1.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.69
Quick Ratio 4.22
Altman-Z 4.38
F-Score4
WACC8.85%
ROIC/WACCN/A
Cap/Depr(3y)49.18%
Cap/Depr(5y)160.46%
Cap/Sales(3y)1.1%
Cap/Sales(5y)1.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-186.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1750%
EPS Next Y-14.27%
EPS Next 2Y-26.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-35.96%
Revenue growth 3Y-37.74%
Revenue growth 5Y-16.22%
Sales Q2Q%-36.9%
Revenue Next Year-27.82%
Revenue Next 2Y-19.23%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-167.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-92.66%
FCF growth 3Y-80.85%
FCF growth 5Y-61.05%
OCF growth 1Y-71.96%
OCF growth 3Y-67.21%
OCF growth 5Y-45.69%

MEDIFAST INC / MED FAQ

What is the ChartMill fundamental rating of MEDIFAST INC (MED) stock?

ChartMill assigns a fundamental rating of 4 / 10 to MED.


Can you provide the valuation status for MEDIFAST INC?

ChartMill assigns a valuation rating of 1 / 10 to MEDIFAST INC (MED). This can be considered as Overvalued.


Can you provide the profitability details for MEDIFAST INC?

MEDIFAST INC (MED) has a profitability rating of 3 / 10.


Can you provide the financial health for MED stock?

The financial health rating of MEDIFAST INC (MED) is 9 / 10.